Personalis (NASDAQ:PSNL) Expected to Post Q3 2019 Earnings of ($0.21) Per Share

Personalis (NASDAQ:PSNL) – Stock analysts at Oppenheimer boosted their Q3 2019 earnings per share (EPS) estimates for Personalis in a research report issued on Wednesday, August 14th. Oppenheimer analyst K. Degeeter now anticipates that the company will post earnings per share of ($0.21) for the quarter, up from their prior estimate of ($0.23). Oppenheimer has a “Outperform” rating and a $29.00 price objective on the stock. Oppenheimer also issued estimates for Personalis’ Q4 2019 earnings at ($0.21) EPS, FY2019 earnings at ($1.09) EPS, FY2020 earnings at ($0.81) EPS and FY2021 earnings at ($0.41) EPS.

Several other equities research analysts have also issued reports on the stock. Bank of America began coverage on shares of Personalis in a report on Monday, July 15th. They issued a “neutral” rating and a $27.00 target price for the company. CIBC began coverage on shares of Personalis in a report on Monday, July 15th. They issued an “outperform” rating and a $29.00 target price for the company. Morgan Stanley began coverage on shares of Personalis in a report on Monday, July 15th. They issued an “overweight” rating and a $28.00 target price for the company. Finally, Cowen began coverage on shares of Personalis in a report on Monday, July 15th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Personalis currently has an average rating of “Buy” and a consensus price target of $28.25.



Personalis stock opened at $19.81 on Monday. The business has a 50-day moving average price of $20.23. Personalis has a 12-month low of $14.25 and a 12-month high of $31.88.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.58). The business had revenue of $15.80 million for the quarter, compared to analyst estimates of $14.92 million. Personalis’s revenue was up 79.5% compared to the same quarter last year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Board of Trustees of The Leland Stanford Junior University bought a new stake in Personalis during the 2nd quarter valued at about $38,749,000. JPMorgan Chase & Co. bought a new stake in Personalis during the 2nd quarter valued at about $17,685,000. Janus Henderson Group PLC bought a new stake in Personalis during the 2nd quarter valued at about $13,554,000. Laurion Capital Management LP bought a new stake in Personalis during the 2nd quarter valued at about $8,472,000. Finally, Orbimed Advisors LLC bought a new stake in Personalis during the 2nd quarter valued at about $8,145,000. Institutional investors own 16.83% of the company’s stock.

In other news, Director Ken Ludlum bought 70,000 shares of the stock in a transaction dated Monday, June 24th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $1,190,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Recommended Story: Are all No-Load Funds Equal?

Earnings History and Estimates for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.